scholarly journals Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients

2018 ◽  
Vol 9 (5) ◽  
pp. 909-919 ◽  
Author(s):  
Sophie A. Kurk ◽  
Petra H.M. Peeters ◽  
Bram Dorresteijn ◽  
Pim A. de Jong ◽  
Marion Jourdan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Skeletal Muscle ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Systemic Treatments ◽  
Colorectal Cancer Patients

scholarly journals Skeletal muscle mass loss and dose‐limiting toxicities in metastatic colorectal cancer patients

2019 ◽  
Vol 10 (4) ◽  
pp. 803-813 ◽  
Author(s):  
Sophie Kurk ◽  
Petra Peeters ◽  
Rebecca Stellato ◽  
B. Dorresteijn ◽  
Pim Jong ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Skeletal Muscle ◽  
Mass Loss ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Muscle Mass Loss ◽  
Colorectal Cancer Patients

scholarly journals The Relationship Between Sarcopenia Detected In Newly Diagnosed Colorectal Cancer Patients And FGF21, Irisin And CRP Levels.

2021 ◽  
Author(s):  
Utku Oflazoglu ◽  
Sevinc Caglar ◽  
Huriye Erbak Yılmaz ◽  
Hülya Tas Önal ◽  
Umut Varol ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Skeletal Muscle ◽  
Cancer Patients ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Negative Relationship ◽  
Newly Diagnosed ◽  
Skeletal Muscle Mass Index ◽  
Colorectal Cancer Patients ◽  
The Relationship

Abstract Aim: Sarcopenia is a progressive and generalized syndrome that can be linked to many causes such as cancers, and is caused by a quantitative and qualitative disorder (loss of muscle strength and / or physical performance) of skeletal muscle mass. Although sarcopenia has some hypothetical explanation in clinical practice, the mechanisms underlying this condition have not been clearly differentiated in patients with cancer. We aimed to investigate the relationship between irisin and FGF21 in detecting sarcopenia in colorectal cancer patients.Material and Method: Current prospectively study included non-metastatic newly diagnosed colorectal cancer patients. Patients were divided into two groups of 25 people, those with and without sarcopenia. Body composition measurements by examined by BIA. To measure the level of iris and FGF21 from patients, blood samples were taken into the biochemistry tube and their levels were measured. Results: The median age of the patients included in the study was 60 years (range: 21-81), 68 % were men. It was found that there was a significant relationship between sarcopenia and gender and BMI measurement. When Spearman correlation analysis was performed between skeletal muscle mass index and FGF21, irisin and CRP, there was a positive correlation between skeletal muscle mass index and irisin and FGF21, while there was a negative correlation between skeletal muscle mass index and CRP. [respectively: (r: 0.282, p: 0.048), (r: 0.564, p: <0.001) and (r: -0.360, p: 0.010). Similar results were found between hand grip strength and FGF21, irisin and CRP. [respectively: (r: 0.342, p: 0.015), (r: 0.290, p: 0.041) and (r: -0.476, p <0.001)]. When sarcopenia was treated as the dependent variable in the logistic regression analysis, and FGF21, irisin, CRP, gender and BMI were treated as the independent variables, irisin and CRP levels were determined as independent predictors. Conclusion: This study was revealed that there is a negative relationship between sarcopenia and irisin and FGF-21 in operated non-metastatic colorectal cancer patients and there may be a relationship between sarcopenia and inflammation. It suggest that these biomarkers may play a role in the pathophysiology of sarcopenia. However, our results need to be validated in different types of cancer and with more patients.

scholarly journals Associations of pre-existing co-morbidities with skeletal muscle mass and radiodensity in patients with non-metastatic colorectal cancer

2018 ◽  
Vol 9 (4) ◽  
pp. 654-663 ◽  
Author(s):  
Jingjie Xiao ◽  
Bette J. Caan ◽  
Erin Weltzien ◽  
Elizabeth M. Cespedes Feliciano ◽  
Candyce H. Kroenke ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Skeletal Muscle ◽  
Metastatic Colorectal Cancer ◽  
Muscle Mass ◽  
Skeletal Muscle Mass

scholarly journals No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Sami Antoun ◽  
Mohamed Amine Bayar ◽  
Valérie Dyevre ◽  
Emilie Lanoy ◽  
Cristina Smolenschi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Skeletal Muscle ◽  
Metastatic Colorectal Cancer ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
First Line ◽  
Line Chemotherapy

Low Skeletal Muscle Mass before Salvage-Line Chemotherapy Is a Poor Prognostic Factor in Patients with Refractory Metastatic Colorectal Cancer

Digestion ◽  
2018 ◽  
Vol 99 (1) ◽  
pp. 79-85 ◽  
Author(s):  
Yuji Miyamoto ◽  
Yukiharu Hiyoshi ◽  
Takahiko Akiyama ◽  
Yuki Kiyozumi ◽  
Kojiro Eto ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Skeletal Muscle ◽  
Prognostic Factor ◽  
Metastatic Colorectal Cancer ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Poor Prognostic Factor ◽  
Line Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document